In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.
A new report highlights how EMA support programs, including scientific advice, PRIME, and fee reductions, are helping biopharma companies reduce early development and market entry costs. The analysis suggests these programs can significantly shorten timelines and lower financial burden, particularly for small and mid-sized innovators.
Early real-world findings show that Carvykti, a BCMA-directed CAR T-cell therapy, is demonstrating sustained remissions in patients with relapsed or refractory multiple myeloma. Clinicians report encouraging durability and deep responses, reinforcing Carvykti’s potential role in later-line treatment.
Pfizer has entered an exclusive collaboration and license agreement with Yao Pharma focused on developing oral small-molecule GLP-1 agonists. The partnership aims to leverage Yao Pharma’s chemistry capabilities and Pfizer’s metabolic disease expertise to expand the next generation of GLP-1–based therapies.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
